Matches in SemOpenAlex for { <https://semopenalex.org/work/W4248836103> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4248836103 endingPage "1506" @default.
- W4248836103 startingPage "1499" @default.
- W4248836103 abstract "Since 1980, adults with acute myelocytic leukemia (AML) have been treated on two clinical studies using intensive timed sequential therapy. All patients ages 16 to 80, including those with secondary AML (SAML) and those with AML preceded by a hematologic disorder (AHD), were treated, regardless of medical complications at the time of diagnosis. The first study combined high doses of cytarabine (ara-C, AC) and daunorubicin (DRN, D) in sequence (Ac2-D-Ac) and resulted in a complete remission rate of 55%. A group of these patients selected by functional status was able to receive a second course of therapy in remission, which resulted in a disease-free survival (DFS) of greater than 40% at 7 years. Because of toxicity in that study, 114 patients were entered on a second trial initiated 4 years ago, using a less aggressive first course, with amsacrine, to achieve a stable remission (Ac2-D-Amsa). This first treatment was followed by a more intensive second course (Ac6-D-Ac). With this two-step approach, a higher complete remission (CR) rate (76% for de novo AML and 54% for SAML-AHD) was achieved, and more patients were able to receive the second course of therapy. At the current median follow-up of 26 months, the median duration of DFS and overall survival are 11 and 14 months for patients with de novo AML. Age less than or equal to 55 is the most significant prognostic factor for both prolonged DFS and overall survival, with median durations of 17 and 18 months, respectively, for these younger patients. Patients with SAML-AHD remain relatively refractory to treatment despite aggressive chemotherapy, with median durations of DFS and overall survival of 9 months and 5 months, respectively." @default.
- W4248836103 created "2022-05-12" @default.
- W4248836103 creator A5001163816 @default.
- W4248836103 creator A5027123893 @default.
- W4248836103 creator A5043598160 @default.
- W4248836103 creator A5053640906 @default.
- W4248836103 creator A5054689382 @default.
- W4248836103 creator A5058320935 @default.
- W4248836103 creator A5069703434 @default.
- W4248836103 creator A5078042962 @default.
- W4248836103 creator A5084207699 @default.
- W4248836103 creator A5088059392 @default.
- W4248836103 date "1989-10-01" @default.
- W4248836103 modified "2023-09-30" @default.
- W4248836103 title "A two-step timed sequential treatment for acute myelocytic leukemia" @default.
- W4248836103 doi "https://doi.org/10.1182/blood.v74.5.1499.bloodjournal7451499" @default.
- W4248836103 hasPublicationYear "1989" @default.
- W4248836103 type Work @default.
- W4248836103 citedByCount "3" @default.
- W4248836103 crossrefType "journal-article" @default.
- W4248836103 hasAuthorship W4248836103A5001163816 @default.
- W4248836103 hasAuthorship W4248836103A5027123893 @default.
- W4248836103 hasAuthorship W4248836103A5043598160 @default.
- W4248836103 hasAuthorship W4248836103A5053640906 @default.
- W4248836103 hasAuthorship W4248836103A5054689382 @default.
- W4248836103 hasAuthorship W4248836103A5058320935 @default.
- W4248836103 hasAuthorship W4248836103A5069703434 @default.
- W4248836103 hasAuthorship W4248836103A5078042962 @default.
- W4248836103 hasAuthorship W4248836103A5084207699 @default.
- W4248836103 hasAuthorship W4248836103A5088059392 @default.
- W4248836103 hasBestOaLocation W42488361031 @default.
- W4248836103 hasConcept C126322002 @default.
- W4248836103 hasConcept C141071460 @default.
- W4248836103 hasConcept C2776694085 @default.
- W4248836103 hasConcept C2778041864 @default.
- W4248836103 hasConcept C2778119113 @default.
- W4248836103 hasConcept C2778461978 @default.
- W4248836103 hasConcept C2780500152 @default.
- W4248836103 hasConcept C2781021840 @default.
- W4248836103 hasConcept C3017948075 @default.
- W4248836103 hasConcept C3018657049 @default.
- W4248836103 hasConcept C71924100 @default.
- W4248836103 hasConcept C90924648 @default.
- W4248836103 hasConceptScore W4248836103C126322002 @default.
- W4248836103 hasConceptScore W4248836103C141071460 @default.
- W4248836103 hasConceptScore W4248836103C2776694085 @default.
- W4248836103 hasConceptScore W4248836103C2778041864 @default.
- W4248836103 hasConceptScore W4248836103C2778119113 @default.
- W4248836103 hasConceptScore W4248836103C2778461978 @default.
- W4248836103 hasConceptScore W4248836103C2780500152 @default.
- W4248836103 hasConceptScore W4248836103C2781021840 @default.
- W4248836103 hasConceptScore W4248836103C3017948075 @default.
- W4248836103 hasConceptScore W4248836103C3018657049 @default.
- W4248836103 hasConceptScore W4248836103C71924100 @default.
- W4248836103 hasConceptScore W4248836103C90924648 @default.
- W4248836103 hasIssue "5" @default.
- W4248836103 hasLocation W42488361031 @default.
- W4248836103 hasOpenAccess W4248836103 @default.
- W4248836103 hasPrimaryLocation W42488361031 @default.
- W4248836103 hasRelatedWork W1020360509 @default.
- W4248836103 hasRelatedWork W1583871986 @default.
- W4248836103 hasRelatedWork W1967042982 @default.
- W4248836103 hasRelatedWork W2004133681 @default.
- W4248836103 hasRelatedWork W2064930805 @default.
- W4248836103 hasRelatedWork W2266306026 @default.
- W4248836103 hasRelatedWork W2406795601 @default.
- W4248836103 hasRelatedWork W2414858770 @default.
- W4248836103 hasRelatedWork W28619365 @default.
- W4248836103 hasRelatedWork W795592684 @default.
- W4248836103 hasVolume "74" @default.
- W4248836103 isParatext "false" @default.
- W4248836103 isRetracted "false" @default.
- W4248836103 workType "article" @default.